LCZ696B

Drug Novartis Pharma AG
Total Payments
$478,293
Transactions
263
Doctors
56
Companies
1

Payment Trends by Year

Year Amount Transactions Doctors
2018 $241,204 174 34
2017 $237,089 89 32

Payments by Nature

Nature of Payment Amount Transactions Share
Consulting Fee $215,624 26 45.1%
Unspecified $134,490 36 28.1%
Travel and Lodging $121,549 119 25.4%
Food and Beverage $6,631 82 1.4%

Payments by Type

General
$343,803
227 transactions
Research
$134,490
36 transactions

Research Studies & Clinical Trials

Study Name Sponsor Amount Doctors
CLCZ696B2320 Novartis Pharma AG $72,982 3
CLCZ696B2319 Novartis Pharma AG $60,427 2
CLCZ696B2314 Novartis Pharma AG $1,080 1

Top Doctors Receiving Payments for LCZ696B — Page 3

Doctor Specialty Location Total Records
, MD Pediatric Cardiology Cleveland, OH $45.13 1
, M.D Clinical Cardiac Electrophysiology Atlanta, GA $45.13 1
, MD Advanced Heart Failure and Transplant Cardiology Cincinnati, OH $45.13 1
, M.D Pediatrics Salt Lake City, UT $45.13 1
, M.D Pediatrics New York, NY $45.13 1
, MD Pediatrics Rochester, MN $45.13 1
, MD Pediatric Cardiology St Petersburg, FL $45.13 1

About LCZ696B

LCZ696B is a drug associated with $478,293 in payments to 56 healthcare providers, recorded across 263 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharma AG.

Payment data is available from 2017 to 2018. In 2018, $241,204 was paid across 174 transactions to 34 doctors.

The most common payment nature for LCZ696B is "Consulting Fee" ($215,624, 45.1% of total).

LCZ696B is associated with 3 research studies, including "CLCZ696B2320" ($72,982).